The Investigation of Relationship between Therapeutic Effect and Prognosis and Changes of Peripheral Blood Vascular Endothelial Growth Factor and Metallothionein in Patients with Advanced Lung Cancer
|School||Zunyi Medical College,|
|Keywords||Lung Cancer Vascular endothelial growth factor Metallothionein|
Objective : To investigate the peripheral blood of patients with advanced lung cancer combined detection of vascular endothelial growth factor (vascular endothelial growth factor, VEGF) and metallothionein (Metallothionein, MT) and histological type of lung cancer , lymph node metastasis, treatment , prognosis relationships. Methods: The experiment was divided into lung cancer ( 33 cases of advanced lung cancer patients ) and control group ( 30 healthy ) ; using double antibody sandwich (ABC-ELISA) method for the determination Serum levels of VEGF and MT ; real-time quantitative reverse transcription polymerase chain reaction (RT-PCR) method were detected VEGF mRNA in peripheral blood mononuclear cells and MT mRNA expression . Results: The serum VEGF, MT levels were (174.3 ± 60.1) pg / ml, (5.7 ± 2.8) ng / ml, lung cancer patients before chemotherapy, VEGF, MT levels were (401.2 ± 142.4) pg / ml, ( 13.9 ± 6.0) ng / ml, lung cancer patients before chemotherapy serum VEGF and MT were significantly higher (P lt; 0.01). Control group blood VEGF mRNA, MT mRNA expression were (48.8 ± 24.1), (95.0 ± 30.3), lung cancer patients before chemotherapy, blood VEGF mRNA, MT mRNA were (209.6 ± 90.3), (184.2 ± 103.2) lung cancer patients before chemotherapy, blood VEGF mRNA, MT mRNA expression were significantly higher (P lt; 0.01). Lung cancer patients after chemotherapy VEGF protein levels below before chemotherapy (P lt; 0.05), while VEGF mRNA in peripheral blood before and after chemotherapy, no difference (P gt; 0.05); MT protein and mRNA in peripheral blood before and after treatment no difference (P gt; 0.05). VEGF and the MT gene and protein expression levels in patients with advanced lung cancer, gender, histological type, lymph node metastasis and efficacy were not correlated , the difference was not statistically significant (P gt; 0.05). MT VEGF in lung cancer group and the positive rates were 78.8% and 63.6% , two kinds of combined detection of tumor markers positive rate rose to 91%. Serum VEGF and MT was no correlation between the measured values ??. Conclusion: Serum VEGF and MT joint detection can increase the positive rate, but no correlation between the two . VEGF, MT joint detection with advanced lung cancer patients gender, histological type, lymph node metastasis , treatment and prognosis of no relevance.